NASDAQ:ALRN - Aileron Therapeutics Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$4.57 -0.07 (-1.51 %)
(As of 07/18/2018 04:00 PM ET)
Previous Close$4.64
Today's Range$4.56 - $4.83
52-Week Range$4.55 - $15.48
Volume101,300 shs
Average Volume35,942 shs
Market Capitalization$71.48 million
P/E Ratio-2.58
Dividend YieldN/A
Aileron Therapeutics logoAileron Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing a novel class of therapeutics in the United States. The company's lead product candidate is ALRN-6924, a stapled peptide, which is in Phase I clinical trial for the treatment of advanced solid tumors or lymphomas; Phase IIa clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS); and Phase IIb trial to treat AML/MDS in combination with cytosine arabinoside. It also develops next generation wild type p53 reactivator that is in preclinical stage for the treatment of solid and liquid tumors. The company was formerly known as Renegade Therapeutics, Inc. and changed its name to Aileron Therapeutics, Inc. in February 2007. Aileron Therapeutics, Inc. was founded in 2001 and is based in Cambridge, Massachusetts.

Receive ALRN News and Ratings via Email

Sign-up to receive the latest news and ratings for ALRN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations


Debt-to-Equity RatioN/A
Current Ratio9.16
Quick Ratio9.16


Trailing P/E Ratio-2.58
Forward P/E Ratio-2.16
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$3.25 per share
Price / Book1.41


EPS (Most Recent Fiscal Year)($1.77)
Net Income$-22,600,000.00
Net MarginsN/A
Return on Equity-461.02%
Return on Assets-58.75%


Outstanding Shares14,740,000
Market Cap$71.48

The Truth About Cryptocurrencies

Aileron Therapeutics (NASDAQ:ALRN) Frequently Asked Questions

What is Aileron Therapeutics' stock symbol?

Aileron Therapeutics trades on the NASDAQ under the ticker symbol "ALRN."

How were Aileron Therapeutics' earnings last quarter?

Aileron Therapeutics Inc (NASDAQ:ALRN) released its earnings results on Wednesday, May, 9th. The company reported ($0.52) EPS for the quarter, missing analysts' consensus estimates of ($0.50) by $0.02. View Aileron Therapeutics' Earnings History.

What price target have analysts set for ALRN?

4 brokerages have issued 12 month price targets for Aileron Therapeutics' stock. Their forecasts range from $19.00 to $20.00. On average, they expect Aileron Therapeutics' stock price to reach $19.3333 in the next year. This suggests a possible upside of 323.0% from the stock's current price. View Analyst Ratings for Aileron Therapeutics.

What is the consensus analysts' recommendation for Aileron Therapeutics?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aileron Therapeutics in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

Who are some of Aileron Therapeutics' key competitors?

Who are Aileron Therapeutics' key executives?

Aileron Therapeutics' management team includes the folowing people:
  • Mr. Donald V. Dougherty CPA, CFA, Sr. VP & CFO (Age 59)
  • Dr. Manuel C. Aivado, Sr. VP, Chief Medical Officer & Chief Scientific Officer (Age 48)
  • Dr. John P. Longenecker, Interim Chief Exec. Officer (Age 58)
  • Ms. Kira A. Nelson CPA, VP of Fin. & Operations (Age 49)
  • Dr. D. Allen Annis, VP of Biophysical & Analytical Technologies

When did Aileron Therapeutics IPO?

(ALRN) raised $61 million in an initial public offering (IPO) on Thursday, June 29th 2017. The company issued 3,800,000 shares at $15.00-$17.00 per share. BofA Merrill Lynch and Jefferies acted as the underwriters for the IPO and William Blair and Canaccord Genuity were co-managers.

Has Aileron Therapeutics been receiving favorable news coverage?

News coverage about ALRN stock has been trending somewhat positive this week, according to Accern Sentiment Analysis. The research group ranks the sentiment of news coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Aileron Therapeutics earned a news sentiment score of 0.12 on Accern's scale. They also gave media headlines about the company an impact score of 46.89 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the near future.

How do I buy shares of Aileron Therapeutics?

Shares of ALRN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Aileron Therapeutics' stock price today?

One share of ALRN stock can currently be purchased for approximately $4.57.

How big of a company is Aileron Therapeutics?

Aileron Therapeutics has a market capitalization of $71.48 million. The company earns $-22,600,000.00 in net income (profit) each year or ($1.77) on an earnings per share basis. Aileron Therapeutics employs 13 workers across the globe.

How can I contact Aileron Therapeutics?

Aileron Therapeutics' mailing address is 281 ALBANY STREET, CAMBRIDGE MA, 02139. The company can be reached via phone at 617-995-0900 or via email at [email protected]

MarketBeat Community Rating for Aileron Therapeutics (NASDAQ ALRN)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  82 (Vote Outperform)
Underperform Votes:  87 (Vote Underperform)
Total Votes:  169
MarketBeat's community ratings are surveys of what our community members think about Aileron Therapeutics and other stocks. Vote "Outperform" if you believe ALRN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ALRN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/18/2018 by Staff

Featured Article: Earnings Per Share

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.